ArticleNeuro-oncology2026
Characterization of focal leptomeningeal extension in patients with brain metastases: A novel entity.
Article in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClassical leptomeningeal disease (cLMD) impacts the entire craniospinal axis, but isolated parenchymal metastases sometimes display focal leptomeningeal extension (fLME) without diffuse LMD elsewhere. We assessed whether patients with fLME can be managed with stereotactic radiation (SRS/SRT) as opposed to whole brain/craniospinal radiation without excess development of marginal recurrences or subsequent cLMD.
methodsWe identified 796 patients with 2,354 newly-diagnosed brain metastases (BrM) without cLMD at diagnosis managed at a tertiary center between 2007 and 2022. Each metastasis was assessed for fLME, defined as isolated leptomeningeal extension of an intact BrM without cytologic or radiographic evidence of cLMD. Multivariable Fine and Gray's models were constructed for the primary outcomes of local recurrence and cLMD development.
resultsAmong 796 patients, 138 (17.3%) displayed evidence of fLME, corresponding to 185 of 2,354 (7.9%) BrM. Patients with versus without fLME did not display excess local recurrences (1-year rate: 4.5% vs. 8.2%, respectively, P = .14; multivariable HR 0.56 [95% CI 0.30-1.07], P = .08), including in lesions managed with SRS/SRT (1-year rate: 4.4% vs. 4.9%, respectively; P = .63; multivariable HR 1.21 [95% CI 0.58-2.50], P = .61). The presence of fLME was not a significant predictor of subsequent cLMD (1-year rate: 5.2% vs. 5.2%, P = .99; multivariable HR 0.87 [95% CI 0.44-1.71], P = .68), including following treatment with SRS/SRT (1-year rate: 6.2% vs. 4.1%, P = .83; multivariable HR 0.92 [95% CI 0.36-2.39], P = .87).
conclusionsWe describe a novel entity, fLME, which displays patterns of intracranial failure similar to parenchymal BrM. Stereotactic approaches may be viable in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.